{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:01:22Z","timestamp":1785229282755,"version":"3.55.0"},"reference-count":28,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Treatment of pemphigoid gestationis (PG) mainly consists of systemic and potent topical corticosteroids. This retrospective case series describes patients with severe PG treated with dupilumab, including serological follow-up, and reviews all published cases. PG was confirmed by direct immunofluorescence (linear C3 and\/or IgG deposition along the basement membrane zone) and serology (IgG epidermal staining on salt-split skin or anti-BP180 NC16A IgG ELISA). Pruritus, quality of life and anti-BP180 NC16A IgG and anti-BP180 NC16A IgE were monitored longitudinally. In 5 pregnant women, dupilumab was initiated with a 600 mg loading dose followed by 300 mg biweekly. Baseline pruritus was severe (NRS 8\u201310), with high DLQI scores (18\u201330). Blistering ceased within 1 week in 2 patients and within 4 weeks in 1. Two patients required weekly dosing for disease control. Systemic corticosteroids were discontinued in 3 patients and tapered to \u226410 mg\/day in 2 before delivery. In one case, anti-BP180 IgG paralleled clinical improvement. Anti-BP180 IgE remained negative. All patients delivered healthy infants. In 10 reported cases, pruritus improved rapidly and systemic corticosteroids were tapered. These findings suggest dupilumab may be a promising corticosteroid-sparing option for PG, with rapid clinical response and a favourable safety profile, despite off-label use in pregnancy.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2026-0669","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:02:54Z","timestamp":1785225774000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characterization and Outcomes of Dupilumab for Pemphigoid Gestationis: A Case Series of Five Patients and Literature Review"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-3528","authenticated-orcid":false,"given":"Joost M.","family":"Meijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0770-136X","authenticated-orcid":false,"given":"Elise J.","family":"Leeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Grabik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-684X","authenticated-orcid":false,"given":"Lisette M.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-1433","authenticated-orcid":false,"given":"Klasiena","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-2163","authenticated-orcid":false,"given":"Jelmer R.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-8609","authenticated-orcid":false,"given":"Sanne J.","family":"Gordijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-2517","authenticated-orcid":false,"given":"Mirthe H.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-9363","authenticated-orcid":false,"given":"Maria C.","family":"Bolling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-216X","authenticated-orcid":false,"given":"Gilles F. H.","family":"Diercks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-6386","authenticated-orcid":false,"given":"Jeroen","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-3674","authenticated-orcid":false,"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"163733","doi-asserted-by":"crossref","unstructured":"Tani N, Kimura Y, Koga H, Kawakami T, Ohata C, Ishii N, et al. Clinical and immunological profiles of 25 patients with pemphigoid gestationis. Br J Dermatol 2015; 172: 120\u2013129.","DOI":"10.1111\/bjd.13374"},{"key":"163734","doi-asserted-by":"crossref","unstructured":"Huilaja L, M\u00e4kikallio K, Sormunen R, Lohi J, Hurskainen T, Tasanen K. Gestational pemphigoid: placental morphology and function. Acta Derm Venereol 2013; 93: 33\u201338.","DOI":"10.2340\/00015555-1370"},{"key":"163735","doi-asserted-by":"crossref","unstructured":"Cristescu MI, Tutunaru CV, Panaitescu A, Voiculescu VM. Gestational pemphigoid\u2014from molecular mechanisms to clinical outcomes: a case report and review of literature. Life 2024; 14: 14.","DOI":"10.3390\/life14111427"},{"key":"163736","doi-asserted-by":"crossref","unstructured":"Daniel BS, Murrell DF. Review of autoimmune blistering diseases: the pemphigoid diseases. J Eur Acad Dermatol Venereol 2019; 33: 1685\u20131694.","DOI":"10.1111\/jdv.15679"},{"key":"163737","doi-asserted-by":"crossref","unstructured":"Genovese G, Derlino F, Cerri A, Moltrasio C, Muratori S, Berti E, et al. A systematic review of treatment options and clinical outcomes in pemphigoid gestationis. Front Med 2020; 7: 604945.","DOI":"10.3389\/fmed.2020.604945"},{"key":"163738","doi-asserted-by":"crossref","unstructured":"Yaghi M, McMullan P, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: an update-part II: lactation. J Am Acad Dermatol 2024; 91: 651\u2013668.","DOI":"10.1016\/j.jaad.2023.10.071"},{"key":"163739","doi-asserted-by":"crossref","unstructured":"Preu\u00df SL, Vorobyev A, Moderegger EL, Terheyden P, Bieber K, Kridin K, et al. Pemphigoid gestationis is associated with an increased risk for adverse pregnancy outcomes: a large-scale propensity-matched retrospective cohort study. J Am Acad Dermatol 2024; 91: 748\u2013750.","DOI":"10.1016\/j.jaad.2024.05.087"},{"key":"163740","doi-asserted-by":"crossref","unstructured":"Riquelme-Mc Loughlin C, Mascar\u00f3 JM Jr. Treatment of pemphigoid gestationis with dupilumab. Clin Exp Dermatol 2021; 46: 1578\u20131579.","DOI":"10.1111\/ced.14765"},{"key":"163741","doi-asserted-by":"crossref","unstructured":"Chen RE, Yokoyama CC, Anadkat MJ. Pemphigoid gestationis treated with dupilumab. JAAD Case Rep 2023; 41: 10\u201312.","DOI":"10.1016\/j.jdcr.2023.08.013"},{"key":"163742","doi-asserted-by":"crossref","unstructured":"Liu Y, Yuan J, Xia Y, Du X, Geng S. A case of pemphigoid gestationis successfully treated with dupilumab. Acad Dermatol Venereol 2023; 37: e1164\u2013e1165.","DOI":"10.1111\/jdv.19171"},{"key":"163743","doi-asserted-by":"crossref","unstructured":"Alvarez Martinez D, Russo G, Fontao L, Laffitte E. Successful therapy of pemphigoid gestationis with dupilumab-a new case. J Eur Acad Dermatol Venereol 2023; 37: e752\u2013e753.","DOI":"10.1111\/jdv.18911"},{"key":"163744","doi-asserted-by":"crossref","unstructured":"Thomas KV, Choi F, Le T, McGuire M, Ethington J, Arkin LM. Dupilumab in the treatment of pemphigoid gestationis. Cutis 2025; 115: 102\u2013104.","DOI":"10.12788\/cutis.1176"},{"key":"163745","doi-asserted-by":"crossref","unstructured":"Phong CH, Lee BA, Grando SA. Dupilumab as a novel steroid-sparing treatment for pemphigoid gestationis: a new case report and review of literature. JAAD Case Rep 2025; 60: 37\u201340.","DOI":"10.1016\/j.jdcr.2025.03.019"},{"key":"163746","doi-asserted-by":"crossref","unstructured":"Calvo Arbeloa M, Arrondo Velasco A, Jimenez PR, Sarobe Carricas M. Effectiveness and safety of off-label dupilumab use for the treatment of pemphigoid gestationis: a new case report. Eur J Hosp Pharm 2025: ejhpharm-2025-004583.","DOI":"10.1136\/ejhpharm-2025-004583"},{"key":"163747","doi-asserted-by":"crossref","unstructured":"Sun C, Zeng YP. A case of pemphigoid gestationis successfully treated with systemic corticosteroids combined with dupilumab. Eur J Dermatol 2025; 35: 320\u2013321.","DOI":"10.1684\/ejd.2025.4912"},{"key":"163748","doi-asserted-by":"crossref","unstructured":"Ryan SL, Alsharqi A. Successful use of dupilumab in the management of recalcitrant pemphigoid gestationis. Australas J Dermatol 2026; 67: 60\u201362.","DOI":"10.1111\/ajd.70007"},{"key":"163749","doi-asserted-by":"crossref","unstructured":"Meijer JM, Diercks GFH, de Lang EWG, Pas HH, Jonkman MF. Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid. JAMA Dermatol 2019; 155: 158\u2013165.","DOI":"10.1001\/jamadermatol.2018.4390"},{"key":"163750","doi-asserted-by":"crossref","unstructured":"Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502\u2013507.","DOI":"10.2340\/00015555-1246"},{"key":"163751","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210\u2013216.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"163752","doi-asserted-by":"crossref","unstructured":"Lamberts A, Kotnik N, Diercks GFH, Meijer JM, Di Zenzo G, Pas HH, et al. IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients. J Eur Acad Dermatol Venereol 2021; 35: 973\u2013980.","DOI":"10.1111\/jdv.16996"},{"key":"163753","doi-asserted-by":"crossref","unstructured":"Khong TY, Mooney EE, Ariel I, Balmus NCM, Boyd TK, Brundler MA, et al. Sampling and definitions of placental lesions: amsterdam Placental Workshop Group consensus statement. Arch Pathol Lab Med 2016; 140: 698\u2013713.","DOI":"10.5858\/arpa.2015-0225-CC"},{"key":"163754","doi-asserted-by":"crossref","unstructured":"Abdelhafez MMA, Ahmed KAM, Daud MNBM, Jeffree MS, Kadir F, Baharuddin DMP, et al. Pemphigoid Gestationis and adverse pregnancy outcomes: a literature review. J Gynecol Obstet Hum Reprod 2022; 51: 102370.","DOI":"10.1016\/j.jogoh.2022.102370"},{"key":"163755","doi-asserted-by":"crossref","unstructured":"Atalay NE, Da\u011f\u0131stanl\u0131 F, \u015eim\u015fek HU, Caliskan E. Evaluation of maternal and fetal findings in patients with pemphigoid gestationis. Int J Gynaecol Obstet 2025; 169: 274\u2013278.","DOI":"10.1002\/ijgo.16086"},{"key":"163756","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Garc\u00eda V, De-Miguel-Balsa E, Ramos-Rinc\u00f3n JM, Belinch\u00f3n-Romero I. Safety of dupilumab therapy for atopic dermatitis during pregnancy: a systematic review and meta-analysis. Acta Derm Venereol 2025; 105: adv41307.","DOI":"10.2340\/actadv.v105.41307"},{"key":"163757","doi-asserted-by":"crossref","unstructured":"Huilaja L, Hurskainen T, Autio-Harmainen H, Hofmann SC, Sormunen R, R\u00e4s\u00e4nen J, et al. Pemphigoid gestationis autoantigen, transmembrane collagen XVII, promotes the migration of cytotrophoblastic cells of placenta and is a structural component of fetal membranes. Matrix Biol 2008; 27: 190\u2013200.","DOI":"10.1016\/j.matbio.2007.10.007"},{"key":"163758","doi-asserted-by":"crossref","unstructured":"Borthwick GM, Sunderland CA, Holmes RC, Black MM, Stirrat GM. Abnormal expression of HLA-DR antigen in the placenta of a patient with pemphigoid gestationis. J Reprod Immunol 1984; 6: 393\u2013396.","DOI":"10.1016\/0165-0378(84)90048-2"},{"key":"163759","doi-asserted-by":"crossref","unstructured":"Horiuchi Y. Th2 shift in pregnancy and labor: An immunological perspective to elucidate the pathogenesis onset of atopy. Am J Reprod Immunol 2023; 90: e13716.","DOI":"10.1111\/aji.13716"},{"key":"163760","unstructured":"Administration USFaD. DUPIXENT\u00ae (dupilumab) injection, for subcutaneous use Initial U.S. Approval: 2017. 2015."}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46596\/54904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46596\/54905","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46596\/54906","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46596\/54904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:03:07Z","timestamp":1785225787000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0669","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}